Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian stock markets shed initial gains
Wed, 29 Feb 01:30 pm

Indian stock markets continued to shed initial gains over the last two hours but are still trading in the green. Barring capital goods and banking stocks, all sectoral indices are trading strong.

The BSE-Sensex is trading up by 102 points and NSE-Nifty is trading up by 20 points. BSE Mid cap and BSE Small cap indices too are trading up by 0.7% and 0.6% respectively. The rupee is trading at 48.95 to the US dollar.

Engineering stocks have been trading mixed with Opto Circuits and Bharat Electric leading the gainers and Shanthi Gears and Areva T&D trading the weakest. As per a leading financial daily, Siemens is aiming for a double -digit growth in revenues by capitalizing on the exponential growth of urban centers. Currently, the urban segment (infrastructure and cities sectors) contributes to 25% of the total business volumes worth Rs 120 bn and offers integrated mobility solutions, building and security technologies, power distribution, smart grid applications, and low and medium-voltage products. The sector comprises rail systems, mobility and logistics, low and medium voltage, smart grid, building technologies, etc. Taking the step in this direction, the company has recently commenced operations at two Greenfield factories in Goa with an investment of Rs 2 bn.

Stocks in the Indian Pharma sector are trading mixed with Fresenius Kabi Onco and Dishman Pharma leading the gainers and Orchid Chemicals and Strides Arcolab trading the weakest. As per a leading financial daily, the U.S market has seen price erosion of upto 70% in sales of Lipitor over past few months. As a result, Indian pharmaceutical majors such as Dr Reddy's Laboratories (DRL) and Lupin that are set to sell Lipitor in the US market by middle of 2012 are likely to be hit. The drug lost its patent protection in November last year and since then it is being sold by three players in US. Of these, Ranbaxy which is the only Indian company selling the drug currently in US (with 180 day marketing exclusivity ending in May 2012) has indicated price erosion of 60 to 70 % in generic Lipitor, much higher than the typical price erosion of 40 to 50 % in other products within such period. Lipitor's sales that had achieved a level of US$13 billion in 2006 came down to US$ 5.5 billion when it went off-patent on November 30, 2011. Both DRL and Lupin were trading in the red.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian stock markets shed initial gains". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.